patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_236230 | REC_0004001 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 2.5 | 72 | female | 2 | 7 | 7 | 5 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:57.834527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961193 | REC_0004002 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.8 | 82 | female | 1 | 10 | 4.1 | 1 | entrectinib 600 mg daily | 23.1 | false | MSS | 2026-03-15T05:35:57.834757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227729 | REC_0004003 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.8 | 80 | female | 2 | 17 | 6.3 | 5 | alectinib 600 mg BID | 9.5 | true | MSI-H | 2026-03-15T05:35:57.834990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995174 | REC_0004004 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.7 | 78 | female | 0 | 9 | 7 | 4 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.835222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374610 | REC_0004005 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 16.8 | 77 | female | 2 | 21 | 6.3 | 7 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.835503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758697 | REC_0004006 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 7.7 | 72 | female | 2 | 13 | 6.5 | 2 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.835733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896119 | REC_0004007 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7 | 71 | female | 1 | 34 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.9 | false | MSS | 2026-03-15T05:35:57.835964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349434 | REC_0004008 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.9 | 77 | female | 0 | 55 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17 | true | MSS | 2026-03-15T05:35:57.836298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404481 | REC_0004009 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.3 | 60 | male | 0 | 16 | 5.5 | 4 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.836543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592031 | REC_0004010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.8 | 63 | male | 0 | 11 | 6.5 | 5 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:57.836791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797944 | REC_0004011 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.6 | 78 | female | 2 | 12 | 5.9 | 7 | pembrolizumab 200 mg q3w | 8.7 | false | MSS | 2026-03-15T05:35:57.837023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289133 | REC_0004012 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.1 | 55 | male | 0 | 17 | 5.9 | 6 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.837258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354067 | REC_0004013 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 14.2 | 56 | female | 0 | 19 | 5.5 | 5 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.837496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593739 | REC_0004014 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 14 | 55 | male | 1 | 25 | 5.8 | 5 | osimertinib 80 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:57.837730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931958 | REC_0004015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 19.1 | 66 | female | 0 | 8 | 6.7 | 7 | osimertinib 80 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:57.837959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316780 | REC_0004016 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 11.1 | 67 | female | 0 | 8 | 5.1 | 1 | entrectinib 600 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:57.838192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917928 | REC_0004017 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.6 | 63 | male | 1 | 10 | 5.6 | 4 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.838424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964750 | REC_0004018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.5 | 75 | female | 2 | 35 | 5.7 | 5 | entrectinib 600 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:57.838703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731397 | REC_0004019 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 11 | 10.2 | 60 | male | 0 | 16 | 5.8 | 6 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:57.838942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450150 | REC_0004020 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.8 | 69 | female | 0 | 23 | 7.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:35:57.839169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890756 | REC_0004021 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 17.2 | 85 | male | 0 | 24 | 5.4 | 7 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:57.839408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527438 | REC_0004022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.6 | 79 | male | 2 | 21 | 5.9 | 6 | entrectinib 600 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:57.839650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414964 | REC_0004023 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.9 | 57 | female | 0 | 17 | 5.5 | 8 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:57.839898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826818 | REC_0004024 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 7.9 | 51 | female | 0 | 22 | 3.5 | 1 | sotorasib 960 mg daily | 19.7 | true | MSS | 2026-03-15T05:35:57.840175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718608 | REC_0004025 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 17 | 62 | female | 1 | 22 | 6.8 | 2 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.840435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224114 | REC_0004026 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 3.8 | 75 | female | 2 | 12 | 4.5 | 5 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.840683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829509 | REC_0004027 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 9.8 | 66 | female | 1 | 9 | 4.6 | 3 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:57.840956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442586 | REC_0004028 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.5 | 60 | male | 1 | 17 | 5.7 | 3 | entrectinib 600 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:57.841238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576566 | REC_0004029 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.7 | 53 | female | 0 | 14 | 3.5 | 7 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:57.841546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487462 | REC_0004030 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.6 | 66 | female | 0 | 19 | 5.3 | 5 | sotorasib 960 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.841835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488217 | REC_0004031 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 28 | 3.9 | 62 | male | 0 | 76 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.4 | false | MSS | 2026-03-15T05:35:57.842272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990047 | REC_0004032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.5 | 66 | male | 1 | 25 | 6 | 5 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:57.842578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184792 | REC_0004033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 2.7 | 67 | female | 1 | 17 | 4.5 | 6 | osimertinib 80 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:57.842828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173934 | REC_0004034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.5 | 88 | female | 1 | 12 | 6.1 | 3 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:57.843070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114165 | REC_0004035 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6 | 78 | female | 2 | 14 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:57.843305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555187 | REC_0004036 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.1 | 64 | male | 0 | 57 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:57.843541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951345 | REC_0004037 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.1 | 72 | female | 2 | 9 | 7 | 8 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.843776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450739 | REC_0004038 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.8 | 55 | female | 1 | 17 | 4.2 | 5 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:35:57.844008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235654 | REC_0004039 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.9 | 73 | female | 1 | 14 | 5.7 | 7 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:35:57.844337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556283 | REC_0004040 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.7 | 63 | male | 0 | 24 | 7 | 7 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:35:57.844582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445306 | REC_0004041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8 | 66 | female | 1 | 12 | 6.9 | 4 | sotorasib 960 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:57.844815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290803 | REC_0004042 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9.5 | 77 | female | 1 | 13 | 6.1 | 6 | sotorasib 960 mg daily | 10 | false | MSS | 2026-03-15T05:35:57.845048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570734 | REC_0004043 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.5 | 62 | male | 1 | 61 | 3.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:57.845284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161034 | REC_0004044 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12.7 | 63 | female | 0 | 18 | 4.3 | 2 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:35:57.845644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657202 | REC_0004045 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.2 | 68 | female | 0 | 17 | 6.9 | 5 | pembrolizumab 200 mg q3w | 7.4 | true | MSS | 2026-03-15T05:35:57.845880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258916 | REC_0004046 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 17.3 | 62 | female | 0 | 27 | 5.3 | 5 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:57.846120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443821 | REC_0004047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 12.4 | 56 | female | 1 | 3 | 7.4 | 6 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:35:57.846365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110147 | REC_0004048 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.8 | 67 | female | 0 | 6 | 5.3 | 6 | alectinib 600 mg BID | 10.9 | true | MSI-H | 2026-03-15T05:35:57.846605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356146 | REC_0004049 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.5 | 71 | female | 1 | 20 | 5.6 | 5 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:57.846835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669246 | REC_0004050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.2 | 57 | male | 1 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:57.847071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949620 | REC_0004051 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 15.8 | 80 | female | 3 | 16 | 6 | 7 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.847308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456671 | REC_0004052 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.3 | 63 | male | 1 | 56 | 7.2 | 5 | pembrolizumab 200 mg q3w | 20.5 | true | MSS | 2026-03-15T05:35:57.847541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431643 | REC_0004053 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.9 | 84 | female | 1 | 20 | 3.5 | 2 | sotorasib 960 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:57.847780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573548 | REC_0004054 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 8.8 | 71 | male | 2 | 19 | 3.9 | 6 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.848010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738048 | REC_0004055 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8.4 | 65 | male | 1 | 52 | 2.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:57.848348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413720 | REC_0004056 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.8 | 61 | male | 0 | 4 | 6.5 | 7 | pembrolizumab 200 mg q3w | 19.8 | false | MSS | 2026-03-15T05:35:57.848597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920747 | REC_0004057 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.5 | 70 | female | 1 | 15 | 7.2 | 8 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:35:57.848921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578781 | REC_0004058 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 18.1 | 69 | female | 0 | 4 | 6.5 | 5 | alectinib 600 mg BID | 6.7 | false | MSS | 2026-03-15T05:35:57.849169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856499 | REC_0004059 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 12.1 | 67 | female | 1 | 10 | 7.2 | 2 | osimertinib 80 mg daily | 25.2 | false | MSI-H | 2026-03-15T05:35:57.849411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625674 | REC_0004060 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.9 | 67 | female | 1 | 24 | 5.8 | 2 | sotorasib 960 mg daily | 23.3 | false | MSI-H | 2026-03-15T05:35:57.849648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381271 | REC_0004061 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.6 | 55 | male | 0 | 20 | 5.9 | 5 | sotorasib 960 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:57.849887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626439 | REC_0004062 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 10.9 | 66 | female | 0 | 18 | 5.1 | 2 | entrectinib 600 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:57.850119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595455 | REC_0004063 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 13.4 | 69 | female | 0 | 7 | 3.8 | 0 | osimertinib 80 mg daily | 31.4 | false | MSI-H | 2026-03-15T05:35:57.850355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266763 | REC_0004064 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.4 | 78 | female | 2 | 13 | 4.8 | 5 | sotorasib 960 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.850589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698726 | REC_0004065 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.2 | 73 | female | 1 | 16 | 6 | 4 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:57.850819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938780 | REC_0004066 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 5.7 | 61 | male | 0 | 7 | 4.5 | 2 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:57.851054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219876 | REC_0004067 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 37 | 4.4 | 66 | male | 0 | 43 | 7.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:57.851285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160065 | REC_0004068 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.2 | 61 | male | 1 | 12 | 4.4 | 4 | alectinib 600 mg BID | 5.5 | false | MSI-H | 2026-03-15T05:35:57.851517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216338 | REC_0004069 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.5 | 67 | female | 0 | 23 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:57.851746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574342 | REC_0004070 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 7.7 | 66 | female | 0 | 26 | 6.4 | 1 | pembrolizumab 200 mg q3w | 21.7 | false | MSS | 2026-03-15T05:35:57.852025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702495 | REC_0004071 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.1 | 75 | female | 2 | 12 | 6.4 | 6 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:57.852309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896473 | REC_0004072 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 12 | 13.4 | 72 | female | 2 | 19 | 6.8 | 3 | entrectinib 600 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:35:57.852553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799076 | REC_0004073 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13 | 69 | male | 0 | 21 | 5.4 | 7 | sotorasib 960 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:57.852792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296086 | REC_0004074 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.6 | 79 | female | 1 | 22 | 4.9 | 4 | entrectinib 600 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:57.853023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450190 | REC_0004075 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.5 | 69 | female | 1 | 14 | 5.1 | 7 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.853250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347357 | REC_0004076 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 13.5 | 65 | female | 0 | 25 | 4.8 | 0 | sotorasib 960 mg daily | 34.6 | false | MSS | 2026-03-15T05:35:57.853489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257132 | REC_0004077 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.6 | 68 | male | 0 | 21 | 4.4 | 7 | sotorasib 960 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:57.853723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122153 | REC_0004078 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.9 | 73 | female | 1 | 1 | 5.5 | 7 | alectinib 600 mg BID | 16.2 | false | MSS | 2026-03-15T05:35:57.853952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641988 | REC_0004079 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.1 | 67 | female | 0 | 10 | 6.1 | 3 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:57.854186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512121 | REC_0004080 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 32 | 5 | 71 | female | 3 | 29 | 6.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 26.4 | false | MSS | 2026-03-15T05:35:57.854416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690187 | REC_0004081 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 7 | 56 | male | 0 | 26 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:57.854650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686202 | REC_0004082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.5 | 70 | female | 2 | 19 | 5.6 | 4 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:57.854880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740464 | REC_0004083 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 8.1 | 75 | female | 2 | 11 | 7 | 1 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:35:57.855184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142622 | REC_0004084 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.4 | 86 | female | 1 | 8 | 5.6 | 2 | alectinib 600 mg BID | 19.4 | true | MSS | 2026-03-15T05:35:57.855424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191904 | REC_0004085 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.1 | 77 | female | 1 | 14 | 5 | 3 | alectinib 600 mg BID | 5.9 | true | MSI-H | 2026-03-15T05:35:57.855656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471384 | REC_0004086 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 32 | 10.4 | 69 | male | 0 | 27 | 7.1 | 0 | osimertinib 80 mg daily | 33.1 | false | MSI-H | 2026-03-15T05:35:57.855892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661245 | REC_0004087 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 72 | female | 1 | 15 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:57.856215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825873 | REC_0004088 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.4 | 77 | female | 1 | 26 | 4.2 | 7 | entrectinib 600 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:57.856466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910834 | REC_0004089 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.5 | 61 | female | 0 | 26 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:57.856715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100404 | REC_0004090 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 11.7 | 70 | female | 2 | 18 | 6.6 | 1 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.856965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411055 | REC_0004091 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.1 | 60 | female | 1 | 11 | 4.3 | 2 | entrectinib 600 mg daily | 19.7 | false | MSI-H | 2026-03-15T05:35:57.857204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113265 | REC_0004092 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 20.5 | 62 | male | 0 | 10 | 4.9 | 2 | entrectinib 600 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.857439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752398 | REC_0004093 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 17.3 | 74 | female | 3 | 11 | 7.5 | 7 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:35:57.857672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325881 | REC_0004094 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5 | 64 | female | 0 | 37 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:57.857908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654143 | REC_0004095 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 5.6 | 67 | male | 1 | 17 | 3.4 | 1 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.858143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172139 | REC_0004096 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.5 | 61 | female | 0 | 7 | 7.1 | 2 | entrectinib 600 mg daily | 23 | true | MSS | 2026-03-15T05:35:57.858449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924205 | REC_0004097 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.7 | 54 | male | 0 | 14 | 3.2 | 5 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:57.858690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267548 | REC_0004098 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 11.7 | 65 | male | 1 | 21 | 7.1 | 1 | osimertinib 80 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:57.858924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141565 | REC_0004099 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 12.8 | 62 | male | 1 | 19 | 6.2 | 5 | entrectinib 600 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:57.859164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429857 | REC_0004100 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.7 | 62 | male | 1 | 12 | 3.3 | 4 | alectinib 600 mg BID | 8.7 | false | MSS | 2026-03-15T05:35:57.859408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.